Agenus | AGEN - Current Liabilities


Agenus reported $249.24M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Agenus USD 249.24M 74.25M Mar/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Celldex Therapeutics USD 51.47M 481K Mar/2026
CSL USD 4.61B 207M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Incyte USD 1.49B 25.52M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
J&J USD 57.72B 3.59B Mar/2026
Jiangsu Hengrui CNY 5.64B 732.51M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 95.94M 52.82M Mar/2026
Merck EUR 9.35B 307M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Northwest Biotherapeutics USD 87.9M 3.98M Sep/2025
Novartis USD 31.37B 4.1B Mar/2026
Novavax USD 342.46M 117.49M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Veracyte USD 56.11M 3.82M Mar/2026